• umbraco.MacroEngines.DynamicXml
    Video Interview of James Barder discussing recent positive market research data on MED2002

    Interview of James Barder, Chief Executive, by Proactive Investors in which James discusses the positive market research data on MED2002 announced on 16 October 2017.

  • umbraco.MacroEngines.DynamicXml
    Video Interview of James Barder discussing the Interim results

    Interview of James Barder, Chief Executive, by Proactive Investors in which he discusses the Interim results for the period ending 30 June 2017 including the Phase III programme for MED2002 and the strategy for CSD500.

  • umbraco.MacroEngines.DynamicXml
    Video Interview of James Barder discussing Church and Dwight license termination

    Interview of James Barder, Chief Executive, by Proactive Investors in which he discusses the change of priorities which sees Futura Medical distributor terminate licensing agreement.

  • umbraco.MacroEngines.DynamicXml
    Video Interview of James Barder

    Video Interview of James Barder discussing a 'critical step' in the development of MED2002

  • umbraco.MacroEngines.DynamicXml
    Elevator Pitch

    CEO James Barder

  • umbraco.MacroEngines.DynamicXml
    Video Interview of James Barder

    Video Interview of James Barder discussing the Preliminary results for the year ended 31 December 2016

  • umbraco.MacroEngines.DynamicXml
    Video Interview of James Barder

    Video Interview of James Barder discussing the significant interest for MED2002, Futura’s erectile dysfunction gel based on Ipsos research

  • umbraco.MacroEngines.DynamicXml
    Video Interview of James Barder

    Video Interview of James Barder discussing the UK licensing agreement for its pain relief gel TPR100 and the launch of CSD500 in Saudi Arabia

  • umbraco.MacroEngines.DynamicXml
    Video Interview of James Barder

    Video Interview of James Barder discussing the MED2002 opportunity and the appointment of Ken James as head of R&D.

  • umbraco.MacroEngines.DynamicXml
    Video Interview of James Barder

    Video Interview of James Barder discussing the £12 million Placing

  • umbraco.MacroEngines.DynamicXml
    Video Interview of James Barder

    Video Interview of James Barder discussing the Interim Results and MED2002

  • umbraco.MacroEngines.DynamicXml
    Video Interview of James Barder

    TTK deal provides "certainty of supply", says Futura chief

  • umbraco.MacroEngines.DynamicXml
    Video Interview of James Barder

    Video Interview of James Barder discussing the MED2002 clinical trial progress

  • umbraco.MacroEngines.DynamicXml
    Video Interview of James Barder

    Video Interview of James Barder - Preliminary results for year ended 31 December 2015

  • umbraco.MacroEngines.DynamicXml
    Shareholder Message

    CEO James Barder gives a shareholder update and outlook on expected news flow for 2016.

  • umbraco.MacroEngines.DynamicXml
    Who We Are

    CEO James Barder introduces Futura Medical and its investment proposition

  • umbraco.MacroEngines.DynamicXml
    Our DermaSys® Technology

    CEO James Barder explains the unique benefits of our transdermal and proprietary technology DermaSys®

  • umbraco.MacroEngines.DynamicXml
    Interview with Proactive Investors

    Futura Medical expects first MED2002 trial study results by June 2016. CEO James Barder is interviewed by Proactive Investors (November 2015)